Flora Peyvandi

List of Publications by Year
in descending order

663 papers	33,075 citations	6613 79 h-index	6471 157 g-index
685 all docs	685 docs citations	685 times ranked	36588 citing authors

#	Article	IF	Citations
1	Genetic studies of body mass index yield new insights for obesity biology. Nature, 2015, 518, 197-206.	27.8	3,823
2	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011, 43, 333-338.	21.4	1,685
3	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New England Journal of Medicine, 2020, 383, 1522-1534.	27.0	1,548
4	Hypercoagulability of COVIDâ€19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 1738-1742.	3.8	1,070
5	Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nature Genetics, 2009, 41, 334-341.	21.4	990
6	Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. British Journal of Haematology, 2012, 158, 323-335.	2.5	700
7	Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2019, 380, 335-346.	27.0	625
8	Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2016, 374, 511-522.	27.0	480
9	Recessively inherited coagulation disorders. Blood, 2004, 104, 1243-1252.	1.4	479
10	New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nature Genetics, 2009, 41, 280-282.	21.4	440
11	A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. New England Journal of Medicine, 2016, 374, 2054-2064.	27.0	414
12	Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. Journal of Thrombosis and Haemostasis, 2012, 10, 615-621.	3.8	362
13	Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2017, 15, 312-322.	3.8	362
14	Genome-Wide Association Identifies Nine Common Variants Associated With Fasting Proinsulin Levels and Provides New Insights Into the Pathophysiology of Type 2 Diabetes. Diabetes, 2011, 60, 2624-2634.	0.6	335
15	The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet, The, 2016, 388, 187-197.	13.7	331
16	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 2005, 106, 1262-1267.	1.4	275
17	The Thrombogram in Rare Inherited Coagulation Disorders: Its Relation to Clinical Bleeding. Thrombosis and Haemostasis, 2002, 88, 576-582.	3.4	261
18	ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica, 2008, 93, 232-239.	3.5	250

#	Article	IF	Citations
19	Rare bleeding disorders: diagnosis and treatment. Blood, 2015, 125, 2052-2061.	1.4	244
20	Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. British Journal of Haematology, 1999, 107, 204-206.	2.5	233
21	Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thrombosis and Haemostasis, 2005, 93, 481-487.	3.4	218
22	Rare coagulation deficiencies. Haemophilia, 2002, 8, 308-321.	2.1	215
23	Complement activation in patients with COVID-19: AÂnovel therapeutic target. Journal of Allergy and Clinical Immunology, 2020, 146, 215-217.	2.9	210
24	Large-Scale Gene-Centric Analysis Identifies Novel Variants for Coronary Artery Disease. PLoS Genetics, 2011, 7, e1002260.	3.5	203
25	No Evidence of Association Between Prothrombotic Gene Polymorphisms and the Development of Acute Myocardial Infarction at a Young Age. Circulation, 2003, 107, 1117-1122.	1.6	191
26	ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2496-2502.	3.8	188
27	Abdominal Aortic Aneurysm Is Associated with a Variant in Low-Density Lipoprotein Receptor-Related Protein 1. American Journal of Human Genetics, 2011, 89, 619-627.	6.2	185
28	Rare Coagulation Disorders. Thrombosis and Haemostasis, 1999, 82, 1207-1214.	3.4	180
29	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology, 2022, 19, 475-495.	13.7	180
30	The ADAMTS13â€von Willebrand factor axis in COVIDâ€19 patients. Journal of Thrombosis and Haemostasis, 2021, 19, 513-521.	3.8	176
31	Pregnancy complications and obstetric care in women with inherited bleeding disorders. Haemophilia, 2013, 19, 1-10.	2.1	173
32	Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. Transfusion, 2014, 54, 1756-1768.	1.6	167
33	ADAMTS13mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Human Mutation, 2010, 31, 11-19.	2.5	165
34	Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. British Journal of Haematology, 2000, 111, 1236-1239.	2.5	152
35	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2014, 61, 148-154.	3.7	149
36	von Willebrand factor cleaving protease (ADAMTSâ€13) and ADAMTSâ€13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. British Journal of Haematology, 2004, 127, 433-439.	2.5	142

#	Article	IF	Citations
37	ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2486-2495.	3.8	142
38	Smoking and the Risk of Mortality and Vascular and Respiratory Events in Patients Undergoing Major Surgery. JAMA Surgery, 2013, 148, 755.	4.3	140
39	ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. British Journal of Haematology, 2007, 138, 534-540.	2.5	135
40	Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. American Journal of Obstetrics and Gynecology, 2009, 201, 12.e1-12.e8.	1.3	130
41	Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. Journal of Thrombosis and Haemostasis, 2012, 10, 1938-1943.	3.8	129
42	A critical appraisal of oneâ€stage and chromogenic assays of factor VIII activity. Journal of Thrombosis and Haemostasis, 2016, 14, 248-261.	3.8	127
43	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. Journal of Autoimmunity, 2021, 116, 102560.	6.5	127
44	Factor X Deficiency. Seminars in Thrombosis and Hemostasis, 2009, 35, 407-415.	2.7	125
45	Fibrinogen replacement therapy for congenital fibrinogen deficiency. Journal of Thrombosis and Haemostasis, 2011, 9, 1687-1704.	3.8	124
46	Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia, 2006, 12, 82-89.	2.1	123
47	Introduction: Rare Bleeding Disorders: General Aspects of Clinical Features, Diagnosis, and Management. Seminars in Thrombosis and Hemostasis, 2009, 35, 349-355.	2.7	123
48	The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood, 2014, 123, 4037-4044.	1.4	123
49	Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. Journal of Thrombosis and Haemostasis, 2006, 4, 1634-1637.	3.8	122
50	Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. British Journal of Haematology, 1998, 102, 626-628.	2.5	121
51	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Internal and Emergency Medicine, 2014, 9, 723-734.	2.0	121
52	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatology, The, 2021, 3, e690-e697.	3.9	121
53	Plateletâ€dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2015, 13, 1345-1350.	3.8	119
54	Factor V Deficiency. Seminars in Thrombosis and Hemostasis, 2009, 35, 382-389.	2.7	114

#	Article	IF	Citations
55	Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood, 2006, 107, 1903-1907.	1.4	111
56	Symptoms of inherited factor V deficiency in 35 Iranian patients. British Journal of Haematology, 1998, 103, 1067-1069.	2.5	109
57	Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 158, 124-134.	1.1	108
58	Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood, 2012, 120, 440-448.	1.4	107
59	Gene Polymorphisms Predicting High Plasma Levels of Coagulation and Fibrinolysis Proteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 755-759.	2.4	103
60	ADAMTS-13 assays in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2010, 8, 631-640.	3.8	103
61	Inhibitor development in haemophilia according to concentrate. Thrombosis and Haemostasis, 2015, 113, 968-975.	3.4	103
62	Redefining outcomes in immune TTP: an international working group consensus report. Blood, 2021, 137, 1855-1861.	1.4	103
63	Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency. Journal of Thrombosis and Haemostasis, 2003, 1, 1852-1853.	3.8	101
64	Pharmacokinetics and safety of fibrinogen concentrate. Journal of Thrombosis and Haemostasis, 2009, 7, 2064-2069.	3.8	100
65	Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells, Molecules, and Diseases, 2003, 30, 264-270.	1.4	95
66	The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica, 2008, 93, 722-728.	3.5	95
67	Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. American Journal of Hematology, 2004, 77, 198-199.	4.1	94
68	Force fluctuations during the Maximum Isometric Voluntary Contraction of the quadriceps femoris in haemophilic patients. Haemophilia, 2007, 13, 65-70.	2.1	94
69	Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2017, 15, 1448-1452.	3.8	94
70	Epidemiology and treatment of congenital fibrinogen deficiency. Thrombosis Research, 2012, 130, S7-S11.	1.7	93
71	Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. Haemophilia, 1997, 3, 242-246.	2.1	92
72	Treatment of rare factor deficiencies other than hemophilia. Blood, 2019, 133, 415-424.	1.4	92

#	Article	IF	Citations
73	Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. British Journal of Haematology, 2000, 111, 1236-1239.	2.5	91
74	CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clinical Pharmacology and Therapeutics, 2004, 75, 198-203.	4.7	90
75	Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 6	2.1	90
76	Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study. Journal of Allergy and Clinical Immunology, 2021, 147, 561-566.e4.	2.9	90
77	Role of von Willebrand factor in the haemostasis. Blood Transfusion, 2011, 9 Suppl 2, s3-8.	0.4	89
78	Thrombosis in Inflammatory Bowel Diseases: Role of Inherited Thrombophilia. American Journal of Gastroenterology, 2005, 100, 2036-2041.	0.4	85
79	Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. British Journal of Haematology, 1998, 100, 773-776.	2.5	84
80	Hemophilic arthropathy: Current knowledge and future perspectives. Journal of Thrombosis and Haemostasis, 2021, 19, 2112-2121.	3.8	84
81	Molecular Analysis of the ERGIC-53 Gene in 35 Families With Combined Factor V-Factor VIII Deficiency. Blood, 1999, 93, 2253-2260.	1.4	83
82	Rare bleeding disorders. Haemophilia, 2008, 14, 202-210.	2.1	82
83	Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. Fertility and Sterility, 2005, 84, 1345-1351.	1.0	81
84	Rare bleeding disorders. Haemophilia, 2006, 12, 137-142.	2.1	76
85	Gender-differences in disease distribution and outcome in hospitalized elderly: Data from the REPOSI study. European Journal of Internal Medicine, 2014, 25, 617-623.	2.2	75
86	ADAMTSâ€13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2012, 10, 1556-1565.	3.8	74
87	Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagulation and Fibrinolysis, 2008, 19, 777-783.	1.0	71
88	Initial experience from a doubleâ€blind, placeboâ€controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. American Journal of Hematology, 2012, 87, 430-432.	4.1	71
89	Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen AÎ±-chain gene are not associated with the decay of the mutant mRNAs. Blood, 2001, 98, 3685-3692.	1.4	68
90	Antiâ€beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. Journal of Thrombosis and Haemostasis, 2007, 5, 2421-2428.	3.8	67

#	Article	IF	Citations
91	Novel aspects of factor XIII deficiency. Current Opinion in Hematology, 2011, 18, 366-372.	2.5	67
92	Rare bleeding disorders â€“ bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency. Haemophilia, 2014, 20, 71-75.	2.1	67
93	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	3.5	67
94	Risk factors for inhibitor development in severe hemophilia A. Thrombosis Research, 2018, 168, 20-27.	1.7	67
95	Molecular Characterisation and Three-Dimensional Structural Analysis of Mutations in 21 Unrelated Families with Inherited Factor VII Deficiency. Thrombosis and Haemostasis, 2000, 84, 250-257.	3.4	67
96	Influence of 9p21.3 Genetic Variants on Clinical and Angiographic Outcomes in Early-Onset Myocardial Infarction. Journal of the American College of Cardiology, 2011, 58, 426-434.	2.8	66
97	Advances in the treatment of bleeding disorders. Journal of Thrombosis and Haemostasis, 2016, 14, 2095-2106.	3.8	66
98	Factor XIII â€“ an under diagnosed deficiency â€“ are we using the right assays?. Journal of Thrombosis and Haemostasis, 2010, 8, 2478-2482.	3.8	65
99	Gynecological and obstetrical manifestations of inherited bleeding disorders in women. Journal of Thrombosis and Haemostasis, 2011, 9, 236-245.	3.8	64
100	Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood, 2008, 111, 5592-5600.	1.4	63
101	Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. Clinical Research in Cardiology, 2016, 105, 912-920.	3.3	63
102	The effect of emicizumab prophylaxis on healthâ€related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia, 2019, 25, 33-44.	2.1	63
103	Molecular Characterization of a Multiethnic Group of 21 Patients with Type 3 von Willebrand Disease. Thrombosis and Haemostasis, 2000, 84, 536-540.	3.4	61
104	Gene mutations and threeâ€dimensional structural analysis in 13 families with severe factor X deficiency. British Journal of Haematology, 2002, 117, 685-692.	2.5	61
105	Future of coagulation factor replacement therapy. Journal of Thrombosis and Haemostasis, 2013, 11, 84-98.	3.8	61
106	A comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia, 2013, 19, 338-342.	2.1	61
107	A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis. Gut, 2020, 69, 1148-1149.	12.1	60
108	The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thrombosis and Haemostasis, 2002, 88, 576-82.	3.4	60

#	Article	IF	Citations
109	A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2021, 19, 1883-1887.	3.8	59
110	Rare bleeding disorders. Haemophilia, 2012, 18, 148-153.	2.1	58
111	Rare Bleeding Disorders: Worldwide Efforts for Classification, Diagnosis, and Management. Seminars in Thrombosis and Hemostasis, 2013, 39, 579-584.	2.7	58
112	Variants of OCTN1â€"2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2006, 23, 497-506.	3.7	57
113	Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). Journal of Thrombosis and Haemostasis, 2008, 6, 1534-1541.	3.8	57
114	Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia. Haemophilia, 2019, 25, 738-746.	2.1	57
115	Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radical Biology and Medicine, 2010, 48, 446-456.	2.9	56
116	TTP and ADAMTS13: When Is Testing Appropriate?. Hematology American Society of Hematology Education Program, 2007, 2007, 121-126.	2.5	54
117	Combined FV and FVIII deficiency. Haemophilia, 2008, 14, 1201-1208.	2.1	54
118	Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact. Fertility and Sterility, 2005, 84, 1338-1344.	1.0	53
119	Treatment of rare factor deficiencies in 2016. Hematology American Society of Hematology Education Program, 2016, 2016, 663-669.	2.5	53
120	The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. Blood, 2006, 108, 1280-1283.	1.4	52
121	Nextâ€generation sequencing study finds an excess of rare, coding singleâ€nucleotide variants of ADAMTS13 in patients with deep vein thrombosis. Journal of Thrombosis and Haemostasis, 2013, 11, 1228-1239.	3.8	52
122	Plasma ADAMTSâ€13 levels and the risk of myocardial infarction: an individual patient data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2015, 13, 1396-1404.	3.8	52
123	Mortality rate and risk factors for gastrointestinal bleeding in elderly patients. European Journal of Internal Medicine, 2019, 61, 54-61.	2.2	52
124	Pulmonary embolism in a young pregnant woman with COVID-19. Thrombosis Research, 2020, 191, 36-37.	1.7	52
125	Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfusion, 2014, 12, 575-98.	0.4	52
126	Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation. British Journal of Haematology, 2006, 134, 187-195.	2.5	51

#	Article	IF	Citations
127	The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease. Journal of Thrombosis and Haemostasis, 2010, 8, 2116-2121.	3.8	50
128	Combined Factor V and Factor VIII Deficiency. Seminars in Thrombosis and Hemostasis, 2009, 35, 390-399.	2.7	49
129	Hypercoagulability Is a Stronger Risk Factor for Ischaemic Stroke than for Myocardial Infarction: A Systematic Review. PLoS ONE, 2015, 10, e0133523.	2.5	49
130	Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24 000 years ago. Blood, 2006, 107, 4666-4668.	1.4	48
131	Genetic sequence analysis of inherited bleeding diseases. Blood, 2013, 122, 3423-3431.	1.4	48
132	Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfusion, 2015, 13, 498-513.	0.4	48
133	Phenotype and genotype report on homozygous and heterozygous patients with congenital factor X deficiency. Haematologica, 2008, 93, 934-938.	3.5	47
134	Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. Atherosclerosis, 2011, 214, 397-403.	0.8	47
135	Factor <scp>XIII</scp> deficiency diagnosis: Challenges and tools. International Journal of Laboratory Hematology, 2018, 40, 3-11.	1.3	47
136	Short-term Exposure to High Altitude Causes Coagulation Activation and Inhibits Fibrinolysis. Thrombosis and Haemostasis, 2002, 87, 342-343.	3.4	46
137	Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. British Journal of Haematology, 2010, 151, 488-494.	2.5	46
138	Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. Journal of Thrombosis and Haemostasis, 2019, 17, 52-62.	3.8	46
139	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	2.9	46
140	Phenotype-genotype characterization of 10 families with severe a subunit factor XIII deficiency. Human Mutation, 2004, 23, 98-98.	2.5	45
141	Polypharmacy in older people: lessons from 10Âyears of experience with the REPOSIÂregister. Internal and Emergency Medicine, 2018, 13, 1191-1200.	2.0	45
142	Efficacy and safety of openâ€label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Journal of Thrombosis and Haemostasis, 2020, 18, 479-484.	3.8	45
143	Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood, 2017, 130, 1757-1759.	1.4	44
144	Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. Journal of Autoimmunity, 2021, 117, 102595.	6.5	44

#	Article	IF	Citations
145	Role of Chloride Ions in Modulation of the Interaction between von Willebrand Factor and ADAMTS-13. Journal of Biological Chemistry, 2005, 280, 23295-23302.	3.4	43
146	Gynaecological and obstetrical problems in women with different bleeding disorders. Haemophilia, 2009, 15, 1291-1299.	2.1	43
147	Ndufc2 Gene Inhibition Is Associated With Mitochondrial Dysfunction and Increased Stroke Susceptibility in an Animal Model of Complex Human Disease. Journal of the American Heart Association, 2016, 5, .	3.7	43
148	Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 808-814.	1.7	43
149	Molecular analysis of the ERGIC-53 gene in 35 families with combined factor V-factor VIII deficiency. Blood, 1999, 93, 2253-60.	1.4	43
150	Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations â€“ A Cause for Concern. Thrombosis and Haemostasis, 2002, 88, 690-691.	3.4	41
151	Arg2074Cys missense mutation in the C2 domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the recombinant protein. Blood, 2003, 101, 173-177.	1.4	41
152	Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population. Journal of Lipid Research, 2010, 51, 3342-3349.	4.2	41
153	Defining Aging Phenotypes and Related Outcomes: Clues to Recognize Frailty in Hospitalized Older Patients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 72, glw188.	3.6	41
154	Exploring the global landscape of genetic variation in coagulation factor XI deficiency. Blood, 2017, 130, e1-e6.	1.4	41
155	Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood, 2017, 129, 1245-1250.	1.4	41
156	Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry. Thrombosis and Haemostasis, 2019, 119, 695-704.	3.4	41
157	Management of pregnancy and delivery in women with inherited bleeding disorders. Seminars in Fetal and Neonatal Medicine, 2011, 16, 311-317.	2.3	40
158	Factor XI deficiency in Iranians: its clinical manifestations in comparison with those of classic hemophilia. Haematologica, 2002, 87, 512-4.	3.5	40
159	Mechanisms of the interaction between twoADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Human Mutation, 2006, 27, 330-336.	2.5	39
160	Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thrombosis and Haemostasis, 2013, 109, 488-496.	3.4	39
161	A twoâ€centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. Haemophilia, 2014, 20, 147-153.	2.1	39
162	Timing and severity of inhibitor development in recombinant versus plasmaâ€derived factor VIII concentrates: a SIPPET analysis. Journal of Thrombosis and Haemostasis, 2018, 16, 39-43.	3.8	39

#	Article	IF	Citations
163	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Advances, 2021, 5, 2137-2141.	5.2	39
164	Clinical and molecular characterization of 6 patients affected by severe deficiency of coagulation factor V: broadening of the mutational spectrum of factor V gene and in vitro analysis of the newly identified missense mutations. Blood, 2003, 102, 3210-3216.	1.4	38
165	Effects ofCYP2C9andVKORC1on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics, 2008, 9, 1237-1250.	1.3	38
166	How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters. Thrombosis Research, 2015, 135, 1186-1190.	1.7	38
167	Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Medicine, 2021, 47, 899-902.	8.2	38
168	Congenital afibrinogenemia: first identification of splicing mutations in the fibrinogen BÎ²-chain gene causing activation of cryptic splice sites. Blood, 2002, 100, 4478-4484.	1.4	37
169	The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 2322-2325.	1.5	37
170	Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity. Thrombosis and Haemostasis, 2019, 119, 1767-1772.	3.4	37
171	Comparison of adverse drug reactions among four COVIDâ€19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites. Journal of Thrombosis and Haemostasis, 2021, 19, 2554-2558.	3.8	37
172	Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica, 2003, 88, 454-8.	3.5	37
173	Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A. Human Gene Therapy, 2022, 33, 432-441.	2.7	37
174	Genetic Architecture of Coronary Artery Disease in the Genome-Wide Era: Implications for the Emerging â€œGolden Dozenâ€•Loci. Seminars in Thrombosis and Hemostasis, 2009, 35, 671-682.	2.7	36
175	ADAMTS13 content in plasmaâ€derived factor VIII/von Willebrand factor concentrates. American Journal of Hematology, 2013, 88, 895-898.	4.1	36
176	Rare coagulation disorders. Thrombosis and Haemostasis, 1999, 82, 1207-14.	3.4	36
177	Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. Journal of Thrombosis and Haemostasis, 2005, 3, 280-286.	3.8	35
178	Early-onset ischaemic stroke: Analysis of 58 polymorphisms in 17 genes involved in methionine metabolism. Thrombosis and Haemostasis, 2010, 104, 231-242.	3.4	35
179	Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2016, 374, 2497-2498.	27.0	35
180	Realâ€life experience in switching to new extended halfâ€life products at European haemophilia centres. Haemophilia, 2019, 25, 946-952.	2.1	35

#	Article	IF	Citations
181	Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood, 2020, 136, 353-361.	1.4	35
182	Dramatic presentation of acquired thombotic thrombocytopenic purpura associated with COVID-19. Haematologica, 2020, 105, e540.	3.5	35
183	Efficacy of prophylaxis and genotypeâ€phenotype correlation in patients with severe Factor X deficiency in Iran. Haemophilia, 2012, 18, 211-215.	2.1	34
184	Minimal factor XIII activity level to prevent major spontaneous bleeds. Journal of Thrombosis and Haemostasis, 2017, 15, 1728-1736.	3.8	34
185	Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica, 2018, 103, e315-e317.	3.5	34
186	Hemostatic alterations in COVID-19. Haematologica, 2021, 106, 1472-1475.	3.5	34
187	The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables. Vox Sanguinis, 2010, 99, 232-238.	1.5	33
188	Anticoagulant Treatment With Rivaroxaban in Severe Protein S Deficiency. Pediatrics, 2013, 132, e1435-e1439.	2.1	33
189	Changes in factor <scp>XIII</scp> level during pregnancy. Haemophilia, 2014, 20, e144-8.	2.1	33
190	Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. Thrombosis and Haemostasis, 2015, 113, 567-576.	3.4	33
191	European principles of inhibitor management in patients with haemophilia. Orphanet Journal of Rare Diseases, 2018, 13, 66.	2.7	33
192	Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity. Haematologica, 2018, 103, 344-350.	3.5	33
193	Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency. Journal of Thrombosis and Haemostasis, 2018, 16, 253-261.	3.8	33
194	Congenital afibrinogenaemia caused by uniparental isodisomy of chromosome 4 containing a novel 15-kb deletion involving fibrinogen AÎ±-chain gene. European Journal of Human Genetics, 2004, 12, 891-898.	2.8	32
195	Carrier Detection and Prenatal Diagnosis of Hemophilia in Developing Countries. Seminars in Thrombosis and Hemostasis, 2005, 31, 544-554.	2.7	32
196	Association and Functional Analyses of MEF2A as a Susceptibility Gene for Premature Myocardial Infarction and Coronary Artery Disease. Circulation: Cardiovascular Genetics, 2009, 2, 165-172.	5.1	32
197	Identification of genetic risk variants for deep vein thrombosis by multiplexed next-generation sequencing of 186 hemostatic/pro-inflammatory genes. BMC Medical Genomics, 2012, 5, 7.	1.5	32
198	Molecular diagnosis of von Willebrand disease. Haemophilia, 2017, 23, 188-197.	2.1	32

#	Article	IF	Citations
199	Firstâ€year results of an expanded humanitarian aid programme for haemophilia in resourceâ€constrained countries. Haemophilia, 2018, 24, 229-235.	2.1	32
200	The ISTH Bleeding Assessment Tool and the risk of future bleeding. Journal of Thrombosis and Haemostasis, 2018, 16, 125-130.	3.8	32
201	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	2.1	32
202	Laboratory testing in hemophilia: Impact of factor and nonâ€factor replacement therapy on coagulation assays. Journal of Thrombosis and Haemostasis, 2020, 18, 1242-1255.	3.8	32
203	Managing hematological cancer patients during the COVID-19 pandemic: anÂESMO-EHA Interdisciplinary Expert Consensus. ESMO Open, 2022, 7, 100403.	4.5	32
204	Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2010, 8, 2053-2062.	3.8	31
205	Measurement and prevalence of circulating ADAMTS13â€specific immune complexes in autoimmune thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2014, 12, 329-336.	3.8	31
206	Pregnancy loss and risk of ischaemic stroke and myocardial infarction. British Journal of Haematology, 2016, 174, 302-309.	2.5	31
207	Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables. Radiologia Medica, 2021, 126, 722-728.	7.7	31
208	Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. Internal and Emergency Medicine, 2021, 16, 1223-1229.	2.0	31
209	Characterization of Two Naturally Occurring Mutations in the Second Epidermal Growth Factor-Like Domain of Factor VII. Blood, 1999, 93, 1237-1244.	1.4	30
210	The natural mutation by deletion of Lys9 in the thrombin A-chain affects the pKa value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na+ binding. FEBS Journal, 2006, 273, 159-169.	4.7	30
211	Central nervous system bleeding in patients with rare bleeding disorders. Haemophilia, 2012, 18, 34-38.	2.1	30
212	Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa) Tj ETQq0 0 0 rgBT /Overlock 10 Haemostasis, 2015, 13, 1459-1467.	3.8	30
213	Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation. British Journal of Clinical Pharmacology, 2018, 84, 2010-2019.	2.4	30
214	Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement. Haematologica, 2019, 104, e380-e382.	3.5	30
215	Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. Thrombosis Research, 2009, 124, S9-S11.	1.7	29
216	Normal reference ranges of antithrombin, protein C and protein S: Effect of sex, age and hormonal status. Thrombosis Research, 2013, 132, e152-e157.	1.7	29

#	Article	IF	Citations
217	Postoperative Outcomes After Laparoscopic Splenectomy Compared With Open Splenectomy. Annals of Surgery, 2013, 257, 1116-1123.	4.2	29
218	Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients. Blood, 2016, 127, 2924-2933.	1.4	29
219	Efficacy and safety of a <scp>VWF</scp>/<scp>FVIII</scp> concentrate (wilate^{Â®}) in inherited von Willebrand disease patients undergoing surgical procedures. Haemophilia, 2017, 23, 264-272.	2.1	29
220	Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor. Blood Reviews, 2019, 38, 100572.	5.7	29
221	Delivery of AAVâ€based gene therapy through haemophilia centresâ€"A need for reâ€evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. Haemophilia, 2021, 27, 967-973.	2.1	29
222	AUTOSOMAL RECESSIVE DEFICIENCIES OF COAGULATION FACTORS. Reviews in Clinical and Experimental Hematology, 2001, 5, 369-388.	0.1	28
223	Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. Blood, 2002, 100, 1347-1353.	1.4	28
224	The Genetic Basis of Coronary Artery Disease: From Candidate Genes to Whole Genome Analysis. Trends in Cardiovascular Medicine, 2008, 18, 157-162.	4.9	28
225	Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura. Haematologica, 2020, 105, 1957-1962.	3.5	28
226	World Federation of Hemophilia Gene Therapy Registry. Haemophilia, 2020, 26, 563-564.	2.1	28
227	Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. Journal of Thrombosis and Haemostasis, 2009, 7, 774-779.	3.8	27
228	Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. Thrombosis and Haemostasis, 2011, 105, 381-385.	3.4	27
229	Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway. Journal of Thrombosis and Haemostasis, 2016, 14, 1603-1614.	3.8	27
230	SIPPET: methodology, analysis and generalizability. Haemophilia, 2017, 23, 353-361.	2.1	27
231	Hemostatic abnormalities in patients with Ehlersâ€"Danlos syndrome. Journal of Thrombosis and Haemostasis, 2018, 16, 2425-2431.	3.8	27
232	Short-term exposure to high altitude causes coagulation activation and inhibits fibrinolysis. Thrombosis and Haemostasis, 2002, 87, 342-3.	3.4	27
233	A rare inherited coagulation disorder: Combined homozygous factor VII and factor X deficiency. American Journal of Hematology, 2004, 77, 90-91.	4.1	26
234	Common variants in the haemostatic gene pathway contribute to risk of early-onset myocardial infarction in the Italian population. Thrombosis and Haemostasis, 2011, 106, 855-864.	3.4	26

#	Article	IF	Citations
235	Global coagulation in myeloproliferative neoplasms. Annals of Hematology, 2013, 92, 1633-1639.	1.8	26
236	Comparison of attitudes towards prenatal diagnosis and termination of pregnancy for haemophilia in Iran and Italy. Haemophilia, 2004, 10, 367-369.	2.1	25
237	Orthopaedic surgery in patients with von Willebrand disease. Haemophilia, 2014, 20, 133-140.	2.1	25
238	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. European Journal of Internal Medicine, 2015, 26, 330-337.	2.2	25
239	Efficacy, safety and pharmacokinetics of a new highâ€purity factor X concentrate in subjects with hereditary factor X deficiency. Haemophilia, 2016, 22, 419-425.	2.1	25
240	Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2503-2512.	3.8	25
241	Congenital afibrinogenemia: intracellular retention of fibrinogen due to a novel W437G mutation in the fibrinogen BÎ²-chain gene. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2003, 1639, 87-94.	3.8	24
242	Mutations in theMCFD2 gene and a novel mutation in theLMAN1 gene in Indian families with combined deficiency of factor V and VIII. American Journal of Hematology, 2005, 79, 262-266.	4.1	24
243	Elevated prepartum fibrinogen levels are not associated with a reduced risk of postpartum hemorrhage. Journal of Thrombosis and Haemostasis, 2012, 10, 1451-1453.	3.8	24
244	Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. Thrombosis Research, 2013, 132, 256-262.	1.7	24
245	New findings on inhibitor development: from registries to clinical studies. Haemophilia, 2017, 23, 4-13.	2.1	24
246	Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura. Thrombosis and Haemostasis, 2018, 118, 1729-1742.	3.4	24
247	Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. Journal of Thrombosis and Haemostasis, 2020, 18, 815-824.	3.8	24
248	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3074-3077.	3.8	24
249	Severe factor V deficiency: exon skipping in the factor V gene causing a partial deletion of the C1 domain. Journal of Thrombosis and Haemostasis, 2003, 1, 1237-1244.	3.8	23
250	Molecular characterization of three novel splicing mutations causing factor V deficiency and analysis of the F5 gene splicing pattern. Haematologica, 2008, 93, 1505-1513.	3.5	23
251	Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA. Blood, 2010, 115, 2065-2072.	1.4	23
252	Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. Internal and Emergency Medicine, 2013, 8, 509-520.	2.0	23

#	Article	IF	Citations
253	Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. Journal of Thrombosis and Haemostasis, 2018, 16, 778-790.	3.8	23
254	Advances in the Treatment of Hemophilia: Implications for Laboratory Testing. Clinical Chemistry, 2019, 65, 254-262.	3.2	23
255	Analysis of Iranian patients allowed the identification of the first truncating mutation in the fibrinogen Bbeta-chain gene causing afibrinogenemia. Haematologica, 2002, 87, 855-9.	3.5	23
256	Mechanistic Studies on ADAMTS13 Catalysis. Biophysical Journal, 2008, 95, 2450-2461.	0.5	22
257	The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura. Haematologica, 2009, 94, 289-293.	3.5	22
258	Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission. Journal of Thrombosis and Haemostasis, 2011, 9, 1744-1751.	3.8	22
259	Non-invasive ventilation in the treatment of sleep-related breathing disorders: A review and update. Revista Portuguesa De Pneumologia, 2014, 20, 324-335.	0.7	22
260	Establishment of a bleeding score as a diagnostic tool for patients with rare bleeding disorders. Thrombosis Research, 2016, 148, 128-134.	1.7	22
261	Genome editing of factor X in zebrafish reveals unexpected tolerance of severe defects in the common pathway. Blood, 2017, 130, 666-676.	1.4	22
262	Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. Endocrine, 2017, 56, 298-307.	2.3	22
263	Burden of mild haemophilia A: Systematic literature review. Haemophilia, 2019, 25, 755-763.	2.1	22
264	COVID-19 multidisciplinary high dependency unit: the Milan model. Respiratory Research, 2020, 21, 260.	3.6	22
265	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfusion, 2020, 18, 143-151.	0.4	22
266	Missense or splicing mutation? The case of a fibrinogen BÎ²-chain mutation causing severe hypofibrinogenemia. Blood, 2004, 103, 3051-3054.	1.4	21
267	A Natural Prothrombin Mutant Reveals an Unexpected Influence of A-chain Structure on the Activity of Human Î±-Thrombin. Journal of Biological Chemistry, 2004, 279, 13035-13043.	3.4	21
268	Mutational screening of six afibrinogenemic patients: Identification and characterization of four novel molecular defects. Thrombosis and Haemostasis, 2007, 97, 546-551.	3.4	21
269	Ageing successfully with haemophilia: A multidisciplinary programme. Haemophilia, 2018, 24, 57-62.	2.1	21
270	Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies. Haematologica, 2020, 105, 2038-2043.	3.5	21

#	Article	IF	Citations
271	Nonsense-mediated mRNA decay in the ADAMTS13 gene caused by a 29-nucleotide deletion. Haematologica, 2008, 93, 1678-1685.	3.5	20
272	Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A. Haemophilia, 2010, 16, 469-473.	2.1	20
273	No association between chromosome 12p13 single nucleotide polymorphisms and earlyâ€onset ischemic stroke. Journal of Thrombosis and Haemostasis, 2010, 8, 1858-1860.	3.8	20
274	Comparison of Thrombin Generation Assay With Conventional Coagulation Tests in Evaluation of Bleeding Risk in Patients With Rare Bleeding Disorders. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 637-644.	1.7	20
275	Procoagulatory State in Inflammatory Bowel Diseases Is Promoted by Impaired Intestinal Barrier Function. Gastroenterology Research and Practice, 2015, 2015, 1-10.	1.5	20
276	Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. Digestive and Liver Disease, 2016, 48, 1208-1213.	0.9	20
277	Product type and other environmental risk factors for inhibitor development in severe hemophilia A. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 220-227.	2.3	20
278	Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERSâ€IPS, an international and collaborative crossâ€sectional study. Journal of Thrombosis and Haemostasis, 2020, 18, 2145-2154.	3.8	20
279	Mutations in the MCFD2 gene are predominant among patients with hereditary combined FV and FVIII deficiency (F5F8D) in India. Haemophilia, 2007, 13, 413-419.	2.1	19
280	Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica, 2010, 95, 1444-1447.	3.5	19
281	Active plateletâ€binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction. Journal of Thrombosis and Haemostasis, 2010, 8, 1653-1656.	3.8	19
282	FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. Thrombosis and Haemostasis, 2014, 112, 297-303.	3.4	19
283	Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy. Haemophilia, 2014, 20, e243-50.	2.1	19
284	Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial. Transfusion, 2018, 58, 413-422.	1.6	19
285	Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register. European Journal of Internal Medicine, 2018, 56, 11-18.	2.2	19
286	How I treat thrombotic thrombocytopenic purpura in pregnancy. Blood, 2020, 136, 2125-2132.	1.4	19
287	Characterization of the neutralizing antiâ€emicizumab antibody in a patient with hemophilia A and inhibitor. Journal of Thrombosis and Haemostasis, 2021, 19, 711-718.	3.8	19
288	Prenatal diagnosis and preimplantation genetic diagnosis: novel technologies and state of the art of PGD in different regions of the world. Haemophilia, 2011, 17, 14-17.	2.1	18

#	Article	IF	Citations
289	Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a caseâ€"control study. Orphanet Journal of Rare Diseases, 2014, 9, 193.	2.7	18
290	Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thrombosis Research, 2015, 136, 168-174.	1.7	18
291	Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels. Journal of Thrombosis and Haemostasis, 2015, 13, 228-236.	3.8	18
292	Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. Liver International, 2017, 37, 1295-1303.	3.9	18
293	â€œIn vitroâ€•correction of the severe factor V deficiencyâ€•related coagulopathy by a novel plasmaâ€•derived factor V concentrate. Haemophilia, 2018, 24, 648-656.	2.1	18
294	Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis. Blood Advances, 2019, 3, 1670-1680.	5.2	18
295	How we make an accurate diagnosis of von Willebrand disease. Thrombosis Research, 2020, 196, 579-589.	1.7	18
296	Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia. Blood, 2021, 137, 3127-3136.	1.4	18
297	A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfusion, 2019, 17, 391-398.	0.4	18
298	A novel polymorphism in intron 1a of the human factor VII gene (G73A): study of a healthy Italian population and of 190 young survivors of myocardial infarction. British Journal of Haematology, 2000, 108, 247-253.	2.5	17
299	Glanzmann thrombasthenia and Bernard-Soulier syndrome in south Iran. International Journal of Laboratory Hematology, 2005, 27, 324-327.	0.2	17
300	Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF). Journal of Biological Chemistry, 2006, 281, 30400-30411.	3.4	17
301	Rare Bleeding Disorders. Seminars in Thrombosis and Hemostasis, 2009, 35, 345-347.	2.7	17
302	Evaluation of an automated platelet-based assay of ristocetin cofactor activity. Haemophilia, 2011, 17, 252-256.	2.1	17
303	Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTSâ€•13. Journal of Thrombosis and Haemostasis, 2011, 9, 1620-1627.	3.8	17
304	The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura. Blood Reviews, 2013, 27, 71-76.	5.7	17
305	Appropriateness of antiplatelet therapy for primary and secondary cardioâ€•and cerebrovascular prevention in acutely hospitalized older people. British Journal of Clinical Pharmacology, 2017, 83, 2528-2540.	2.4	17
306	Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients. Archives of Gerontology and Geriatrics, 2017, 69, 21-30.	3.0	17

#	Article	IF	Citations
307	ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura. European Journal of Internal Medicine, 2017, 39, 79-83.	2.2	17
308	Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. Drugs and Aging, 2018, 35, 365-373.	2.7	17
309	Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes. Journal of Thrombosis and Haemostasis, 2018, 16, 2432-2441.	3.8	17
310	How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease. Blood, 2020, 136, 1125-1133.	1.4	17
311	X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers. European Journal of Human Genetics, 2021, 29, 241-249.	2.8	17
312	Prevalence of Disease and Relationships between Laboratory Phenotype and Bleeding Severity in Platelet Primary Secretion Defects. PLoS ONE, 2013, 8, e60396.	2.5	17
313	How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues. Polish Archives of Internal Medicine, 2018, 128, 379-385.	0.4	17
314	National and international registries of rare bleeding disorders. Blood Transfusion, 2008, 6 Suppl 2, s45-8.	0.4	17
315	Molecular genetic analysis of severe coagulation factor XI deficiency in six Italian patients. Haematologica, 2004, 89, 1332-40.	3.5	17
316	Allele Frequency of CYP2C9 Gene Polymorphisms in Iran. Thrombosis and Haemostasis, 2002, 88, 874-875.	3.4	16
317	Role of the 2 adenine (g.11293_11294insAA) insertion polymorphism in the 3â€² untranslated region of the factor VII (FVII) gene: molecular characterization of a patient with severe FVII deficiency. Human Mutation, 2005, 26, 455-461.	2.5	16
318	Spontaneous splenic rupture in a patient with factor XIII deficiency and a novel mutation. Pediatric Blood and Cancer, 2008, 50, 113-114.	1.5	16
319	Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran. Blood Coagulation and Fibrinolysis, 2011, 22, 396-401.	1.0	16
320	Measurement of antiâ€ADAMTS13 neutralizing autoantibodies: a comparison between CBA and FRET assays. Journal of Thrombosis and Haemostasis, 2012, 10, 1439-1442.	3.8	16
321	Management of orthopaedic surgery in rare bleeding disorders. Haemophilia, 2014, 20, 693-701.	2.1	16
322	Longâ€term prophylaxis in severe factor <scp>VII</scp> deficiency. Haemophilia, 2015, 21, 812-819.	2.1	16
323	Treatment of Hemophilia in the Near Future. Seminars in Thrombosis and Hemostasis, 2015, 41, 838-848.	2.7	16
324	Consensus statements on vaccination in patients with haemophiliaâ€"Results from the Italian haemophilia and vaccinations (HEVA) project. Haemophilia, 2019, 25, 656-667.	2.1	16

#	Article	IF	Citations
325	Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound?. Journal of Ultrasound, 2021, 24, 165-173.	1.3	16
326	Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study. Blood, 2015, 126, 5-5.	1.4	16
327	Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. Biomedicines, 2022, 10, 249.	3.2	16
328	Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15-base pair insertion in the F7 gene. Blood, 2001, 97, 960-965.	1.4	15
329	Pitfalls in molecular diagnosis in a family with severe factor VII (FVII) deficiency?misdiagnosis by direct sequence analysis using a PCR product. Prenatal Diagnosis, 2003, 23, 731-734.	2.3	15
330	Congenital hypofibrinogenemia: Characterization of two missense mutations affecting fibrinogen assembly and secretion. Blood Cells, Molecules, and Diseases, 2008, 41, 292-297.	1.4	15
331	The typeÂ2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress. Journal of Thrombosis and Haemostasis, 2013, 11, 1688-1698.	3.8	15
332	A synonymous (c.3390C>T) or a spliceâ€site (c.3380â€2A>G) mutation causes exonÂ26 skipping in four patients with von Willebrand disease (2A/IIE). Journal of Thrombosis and Haemostasis, 2013, 11, 1251-1259.	3.8	15
333	Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 <scp>AICE</scp> survey. Haemophilia, 2014, 20, e128-35.	2.1	15
334	Assaying <scp>FVIII</scp> activity: one method is not enough, and never was. Haemophilia, 2014, 20, 301-303.	2.1	15
335	How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. Clinical Chemistry and Laboratory Medicine, 2015, 53, 265-73.	2.3	15
336	Pregnancy outcome after a first episode of cerebral vein thrombosis. Journal of Thrombosis and Haemostasis, 2016, 14, 2386-2393.	3.8	15
337	Kreuth <scp>IV</scp>: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia, 2017, 23, 370-375.	2.1	15
338	Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome. Seminars in Thrombosis and Hemostasis, 2019, 45, 036-042.	2.7	15
339	Management of rare acquired bleeding disorders. Hematology American Society of Hematology Education Program, 2019, 2019, 80-87.	2.5	15
340	Risk of pregnancy-related venous thromboembolism and obstetrical complications in women with inherited type I antithrombin deficiency: a retrospective, single-centre, cohort study. Lancet Haematology,the, 2020, 7, e320-e328.	4.6	15
341	Healthâ€related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitorsâ€"A nonâ€interventional study. Haemophilia, 2021, 27, 398-407.	2.1	15
342	Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thrombosis and Haemostasis, 2000, 84, 536-40.	3.4	15

#	Article	IF	Citations
343	Inhibitor development in non-severe haemophilia across Europe. Thrombosis and Haemostasis, 2015, 114, 670-675.	3.4	14
344	The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2016, 115, 51-62.	3.4	14
345	Recurrence and Mortality in Young Women With Myocardial Infarction or Ischemic Stroke. JAMA Internal Medicine, 2016, 176, 134.	5.1	14
346	Hemophilia gene therapy knowledge and perceptions: Results of an international survey. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 644-651.	2.3	14
347	Where do we stand with antithrombotic prophylaxis in patients with COVID-19?. Thrombosis Research, 2020, 191, 29.	1.7	14
348	Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. Journal of Thrombosis and Haemostasis, 2021, 19, 32-41.	3.8	14
349	Von Willebrand disease type 2N: An update. Journal of Thrombosis and Haemostasis, 2021, 19, 909-916.	3.8	14
350	Performance of Clinical Laboratories for DNA Analyses to Detect Thrombophilia Mutations. Clinical Chemistry, 2005, 51, 1310-1311.	3.2	13
351	Genetic characterization of patients with Bernard-Soulier syndrome and their relatives from Southern Iran. Platelets, 2007, 18, 409-413.	2.3	13
352	Knowledge and Therapeutic Gaps. American Journal of Preventive Medicine, 2011, 41, S324-S331.	3.0	13
353	Non-invasive tool for foetal sex determination in early gestational age. Haemophilia, 2011, 17, 952-956.	2.1	13
354	Association of a single nucleotide polymorphism of the NPR3 gene promoter with early onset ischemic stroke in an Italian cohort. European Journal of Internal Medicine, 2013, 24, 80-82.	2.2	13
355	Raised haematocrit concentration and the risk of death and vascular complications after major surgery. British Journal of Surgery, 2013, 100, 1030-1036.	0.3	13
356	Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban. International Journal of Hematology, 2016, 103, 165-172.	1.6	13
357	Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PROâ€RBDD project laboratories. International Journal of Laboratory Hematology, 2017, 39, 653-662.	1.3	13
358	High rate of sustained virological response with directâ€acting antivirals in haemophiliacs with HCV infection: A multicenter study. Liver International, 2020, 40, 1062-1068.	3.9	13
359	An international registry of patients with plasminogen deficiency (HISTORY). Haematologica, 2020, 105, 554-561.	3.5	13
360	ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis. Thrombosis Research, 2021, 197, 132-137.	1.7	13

#	Article	IF	Citations
361	Efficacy and safety of fibrinogen concentrate for onâ€demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency. Haemophilia, 2021, 27, 283-292.	2.1	13
362	Subclinical myopathic changes in COVID-19. Neurological Sciences, 2021, 42, 3973-3979.	1.9	13
363	Prognostic value of copeptin and midâ€regional proadrenomedullin in COVIDâ€19â€hospitalized patients. European Journal of Clinical Investigation, 2022, 52, e13753.	3.4	13
364	Molecular characterisation and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency. Thrombosis and Haemostasis, 2000, 84, 250-7.	3.4	13
365	Homozygous 2bp Deletion in the Human Factor VII Gene: A Non-Lethal Mutation that Is Associated with a Complete Absence of Circulating Factor VII. Thrombosis and Haemostasis, 2000, 84, 635-637.	3.4	12
366	Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients. Journal of Thrombosis and Haemostasis, 2003, 1, 2252-2253.	3.8	12
367	Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis. Blood Coagulation and Fibrinolysis, 2007, 18, 81-84.	1.0	12
368	Post-partum hemorrhage in women with rare bleeding disorders. Thrombosis Research, 2011, 127, S116-S119.	1.7	12
369	Arg77His and Trp187Arg are the Most Common Mutations Causing FXIII Deficiency in Iran. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 100-103.	1.7	12
370	Genetic background and risk of postpartum haemorrhage: results from an Italian cohort of 3219 women. Haemophilia, 2014, 20, e377-83.	2.1	12
371	Integrated postural analysis in children with haemophilia. Haemophilia, 2014, 20, 263-267.	2.1	12
372	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2002-2012.	4.5	12
373	Procoagulant imbalance in preterm neonates detected by thrombin generation procedures. Thrombosis Research, 2020, 185, 96-101.	1.7	12
374	High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis. Blood Transfusion, 2018, 16, 215-220.	0.4	12
375	Fibrinogen Mumbai: intracellular retention due to a novel G434D mutation in the Bbeta-chain gene. Haematologica, 2006, 91, 628-33.	3.5	12
376	Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results. Blood, 2022, 140, 89-98.	1.4	12
377	Addressing the complexity of cardiovascular disease by design. Lancet, The, 2011, 377, 356-358.	13.7	11
378	Congenital factor <scp>XIII</scp> deficiency in Pakistan: characterization of seven families and identification of four novel mutations. Haemophilia, 2014, 20, 568-574.	2.1	11

#	Article	IF	Citations
379	Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination. Journal of Thrombosis and Haemostasis, 2015, 13, 1806-1814.	3.8	11
380	<scp>FVIII</scp> inhibitor development according to concentrate: data from the <scp>EUHASS</scp> registry excluding overlap with other studies. Haemophilia, 2016, 22, e36-8.	2.1	11
381	Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study. Thrombosis Research, 2016, 141, 153-157.	1.7	11
382	Inhibitor development in haemophilia. Haemophilia, 2017, 23, 3-3.	2.1	11
383	Minimal dataset for postâ€registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 1878-1881.	3.8	11
384	The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age. Thrombosis Research, 2020, 187, 197-201.	1.7	11
385	Adoption of emicizumab (HemlibraÂ®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey. Haemophilia, 2021, 27, 736-743.	2.1	11
386	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Blood Advances, 2021, 5, 2987-3001.	5.2	11
387	Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection. Thrombosis Research, 2021, 204, 32-39.	1.7	11
388	Caplacizumab, Anti-Vwf Nanobody Potentially Changing the Treatment Paradigm in Thrombotic Thrombocytopenic Purpura: Results of the TITAN Trial. Blood, 2014, 124, 229-229.	1.4	11
389	Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma. Clinical Chemistry and Laboratory Medicine, 2021, 59, 365-371.	2.3	11
390	The European Haemophilia Network (EUHANET). Blood Transfusion, 2014, 12 Suppl 3, s515-8.	0.4	11
391	Molecular characterization of the first missense mutation in the fibrinogen Aalpha-chain gene identified in a compound heterozygous afibrinogenemic patient. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 781-787.	3.8	10
392	Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patients. American Journal of Hematology, 2012, 87, 870-874.	4.1	10
393	Key insights to understand the immunogenicity of FVIII products. Thrombosis and Haemostasis, 2016, 116, S2-S9.	3.4	10
394	Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2016, 14, 2356-2367.	3.8	10
395	Profiling the mutational landscape of coagulation factor V deficiency. Haematologica, 2020, 105, e180-e185.	3.5	10
396	COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia. Clinical Microbiology and Infection, 2020, 26, 1576-1578.	6.0	10

#	Article	IF	Citations
397	Perceived well-being and mental health in haemophilia. Psychology, Health and Medicine, 2020, 25, 1062-1072.	2.4	10
398	Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC. Haemophilia, 2022, 28, .	2.1	10
399	A critical role for Gly25 in the B chain of human thrombin. Journal of Thrombosis and Haemostasis, 2005, 3, 139-145.	3.8	9
400	Requirements for research investigations to clarify the relationships and management of menstrual abnormalities in women with hemostatic disorders. Fertility and Sterility, 2005, 84, 1360-1365.	1.0	9
401	A novel mutation of Î±2-plasmin inhibitor gene causes an inherited deficiency and a bleeding tendency. Haemophilia, 2007, 14, 071027033511002-???.	2.1	9
402	Autoimmune hemophilia at rescue. Haematologica, 2009, 94, 459-461.	3.5	9
403	Polymorphic mi<scp>RNA</scp>â€mediated gene contribution to inhibitor development in haemophilia A. Haemophilia, 2012, 18, 1003-1007.	2.1	9
404	Thrombin generation in patients with idiopathic sudden sensorineural hearing loss. Thrombosis Research, 2014, 133, 1130-1134.	1.7	9
405	A recurrent F8 mutation (c.6046C>T) causing hemophilia A in 8% of northern Italian patients: evidence for a founder effect. Molecular Genetics & Genomic Medicine, 2016, 4, 152-159.	1.2	9
406	Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents. Haemophilia, 2016, 22, e292-300.	2.1	9
407	Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie SocietÃ Italiana di Medicina) Tj ETQq1 1 0.784314 rgBT /Over	2.7	9
408	Complications of whole-exome sequencing for causal gene discovery in primary platelet secretion defects. Haematologica, 2019, 104, 2084-2090.	3.5	9
409	Rare variants lowering the levels of coagulation factor X are protective against ischemic heart disease. Haematologica, 2020, 105, e365-e369.	3.5	9
410	Immune Responses to Plasma-Derived Versus Recombinant FVIII Products. Frontiers in Immunology, 2020, 11, 591878.	4.8	9
411	Assessment of Platelet Thrombus Formation under Flow Conditions in Adult Patients with COVID-19: An Observational Study. Thrombosis and Haemostasis, 2021, 121, 1087-1096.	3.4	9
412	Vaccination against COVIDâ€19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia, 2021, 27, 515-518.	2.1	9
413	IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2021, 32, 1227-1235.	6.1	9
414	Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors. Vaccines, 2021, 9, 1011.	4.4	9

#	Article	IF	Citations
415	Autoimmune Protein S Deficiency and Deep Vein Thrombosis after Chickenpox. Thrombosis and Haemostasis, 1996, 75, 212-213.	3.4	9
416	Single Nucleotide Variant rs2232710 in the Protein Z-Dependent Protease Inhibitor (ZPI, SERPINA10) Gene Is Not Associated with Deep Vein Thrombosis. PLoS ONE, 2016, 11, e0151347.	2.5	9
417	Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study. Journal of Clinical Medicine, 2021, 10, 5959.	2.4	9
418	Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No. Journal of Thrombosis and Haemostasis, 2008, 6, 1450-1452.	3.8	8
419	Management of bleeding disorders in adults. Haemophilia, 2012, 18, 24-36.	2.1	8
420	Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients. Thrombosis Research, 2013, 132, 116-122.	1.7	8
421	Pediatric requirements in Europe stymie help for hemophilia. Nature Medicine, 2014, 20, 117-117.	30.7	8
422	A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking. Thrombosis Research, 2014, 133, 481-487.	1.7	8
423	Mediterranean spotted fever and hearing impairment: a rare complication. International Journal of Infectious Diseases, 2015, 35, 34-36.	3.3	8
424	Management of pregnancy in type 2B von Willebrand disease: case report and literature review. Haemophilia, 2015, 21, e98-103.	2.1	8
425	Involvement of the IgEâ€basophil system and mild complement activation in haemophilia B with antiâ€factor IX neutralizing antibodies and anaphylaxis. Haemophilia, 2017, 23, e348-e353.	2.1	8
426	Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards. European Journal of Internal Medicine, 2018, 52, e12-e14.	2.2	8
427	International Society on Thrombosis and Haemostasis core curriculum project: Core competencies in laboratory thrombosis and hemostasis. Journal of Thrombosis and Haemostasis, 2019, 17, 1848-1859.	3.8	8
428	Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. Liver International, 2019, 39, 2309-2316.	3.9	8
429	Body mass index reduction improves the baseline procoagulant imbalance of obese subjects. Journal of Thrombosis and Thrombolysis, 2019, 48, 52-60.	2.1	8
430	Prevalence of the age-related diseases in older patients with acquired thrombotic thrombocytopenic purpura. European Journal of Internal Medicine, 2020, 75, 79-83.	2.2	8
431	Plasma levels of extracellular vesicles and the risk of post-operative pulmonary embolism in patients with primary brain tumors: a prospective study. Journal of Thrombosis and Thrombolysis, 2021, 52, 224-231.	2.1	8
432	Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia. Haematologica, 2021, 106, 3021-3024.	3.5	8

#	Article	IF	Citations
433	Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys. Blood Reviews, 2021, 49, 100828.	5.7	8
434	Factor VII gene polymorphisms are not associated with myocardial infarction in young women. Journal of Thrombosis and Haemostasis, 2005, 3, 803-804.	3.8	7
435	Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran. Internal and Emergency Medicine, 2006, 1, 35-39.	2.0	7
436	Factor XI deficiency in Southern Iran: identification of a novel missense mutation. Annals of Hematology, 2009, 88, 359-363.	1.8	7
437	Preoperative Hematocrit Concentration and the Risk of Stroke in Patients Undergoing Isolated Coronary-Artery Bypass Grafting. Anemia, 2013, 2013, 1-7.	1.7	7
438	Joint <scp>WFH</scp>â€<scp>ISTH</scp> session: issues in clinical trial design. Haemophilia, 2014, 20, 137-144.	2.1	7
439	Design of clinical trials for new products in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2015, 13, 876-879.	3.8	7
440	Frequency of the p.Gly262Asp mutation in congenital Factor X deficiency. European Journal of Clinical Investigation, 2015, 45, 1087-1091.	3.4	7
441	The thrombin generation assay distinguishes inhibitor from nonâ€inhibitor patients with severe haemophilia A. Haemophilia, 2016, 22, e286-91.	2.1	7
442	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with ageâ€matched controls. Haemophilia, 2018, 24, 726-732.	2.1	7
443	An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASSâ€VWF study. Journal of Thrombosis and Haemostasis, 2018, 16, 1604-1613.	3.8	7
444	Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study. BMJ Open, 2019, 9, e028012.	1.9	7
445	Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia. Annals of Hematology, 2019, 98, 2847-2849.	1.8	7
446	Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease. Haemophilia, 2020, 26, 298-305.	2.1	7
447	Pharmacokinetics, surrogate efficacy and safety evaluations of a new human plasma-derived fibrinogen concentrate (FIB Grifols) in adult patients with congenital afibrinogenemia. Thrombosis Research, 2021, 199, 110-118.	1.7	7
448	Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease. Journal of Thrombosis and Haemostasis, 2021, 19, 96-106.	3.8	7
449	Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. Journal of Thrombosis and Haemostasis, 2021, 19, 21-31.	3.8	7
450	Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis. PLoS ONE, 2016, 11, e0165665.	2.5	7

#	Article	IF	Citations
451	Persistent and severe hypoglycemia associated with trimethoprim-sulfamethoxazole in a frail diabetic man on polypharmacy: A case report and literature review. International Journal of Clinical Pharmacology and Therapeutics, 2018, 56, 86-89.	0.6	7
452	Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1660-e1672.	3.6	7
453	Efficacy and Safety of Azathioprine during Remission of Immune-Mediated Thrombotic Thrombocytopenic Purpura. Blood, 2021, 138, 773-773.	1.4	7
454	Mutational screening of six afibrinogenemic patients: identification and characterization of four novel molecular defects. Thrombosis and Haemostasis, 2007, 97, 546-51.	3.4	7
455	Simvastatin Prevents Liver Microthrombosis and Sepsis Induced Coagulopathy in a Rat Model of Endotoxemia. Cells, 2022, 11, 1148.	4.1	7
456	Prothrombin Mutation Conveying Antithrombin Resistance. New England Journal of Medicine, 2012, 367, 1069-1070.	27.0	6
457	von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2012, 10, 728-730.	3.8	6
458	A two-step approach (Enzyme-linked immunosorbent assay and confirmation assay) to detect antibodies against von Willebrand factor in patients with Acquired von Willebrand Syndrome. Thrombosis Research, 2014, 134, 1316-1322.	1.7	6
459	Thrombotic microangiopathy without renal involvement: two novel mutations in complementâ€regulator genes. Journal of Thrombosis and Haemostasis, 2016, 14, 340-345.	3.8	6
460	Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 1668-1672.	3.8	6
461	von Willebrand disease type 1 mutation p.Arg1379Cys and the variant p.Ala1377Val synergistically determine a 2M phenotype in four Italian patients. Haemophilia, 2016, 22, e502-e511.	2.1	6
462	Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories. International Journal of Laboratory Hematology, 2017, 39, 350-358.	1.3	6
463	Acquired Von Willebrand syndrome and response to desmopressin. Haemophilia, 2018, 24, e25-e28.	2.1	6
464	Molecular investigation of 41 patients affected by coagulation factor <scp>XI</scp> deficiency. Haemophilia, 2018, 24, e50-e55.	2.1	6
465	European principles of inhibitor management in patients with haemophilia: implications of new treatment options. Orphanet Journal of Rare Diseases, 2020, 15, 219.	2.7	6
466	Hemostasis in pregnant women with COVIDâ€19. International Journal of Gynecology and Obstetrics, 2021, 152, 268-269.	2.3	6
467	Risk factors for mortality in hospitalized patients with COVID-19: a study in Milan, Italy. Infectious Diseases, 2021, 53, 226-229.	2.8	6
468	Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency. Blood Reviews, 2021, 50, 100833.	5.7	6

#	Article	IF	Citations
469	No changes of parameters nor coagulation activation in healthy subjects vaccinated for SARS-Cov-2. Thrombosis Update, 2021, 4, 100059.	0.9	6
470	Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis. PLoS ONE, 2021, 16, e0258675.	2.5	6
471	Thrombin Generation Assay During Orthopaedic Surgery In Hemophilia A With and Without Inhibitors: Results From In Vivo Studies. Blood, 2013, 122, 3591-3591.	1.4	6
472	Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations--a cause for concern. Thrombosis and Haemostasis, 2002, 88, 690-1.	3.4	6
473	Intracranial Haemorrhage in Haemophilia Patients Is Still an Open Issue: The Final Results of the Italian EMO.REC Registry. Journal of Clinical Medicine, 2022, 11, 1969.	2.4	6
474	Effects of Antibody Responses to Pre-Existing Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients. Microorganisms, 2022, 10, 1191.	3.6	6
475	The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency. British Journal of Haematology, 2004, 127, 576-584.	2.5	5
476	Thrombophilia Screening: Little Role for the JAK2V617F Mutation. Mayo Clinic Proceedings, 2008, 83, 398-399.	3.0	5
477	B and T lymphocytes in acquired Thrombotic Thrombocytopenic Purpura during disease remission. Thrombosis Research, 2011, 128, 590-592.	1.7	5
478	Assessment of Clotting Factor Concentratesâ€"Pivotal Studies and Long-Term Requirements. Seminars in Thrombosis and Hemostasis, 2015, 41, 855-859.	2.7	5
479	Congenital and acquired ADAMTS13 deficiency: Two mechanisms, one patient. Journal of Clinical Apheresis, 2015, 30, 252-256.	1.3	5
480	Genomic approaches to bleeding disorders. Haemophilia, 2016, 22, 42-45.	2.1	5
481	Degradation of two novel congenital TTP ADAMTS13 mutants by the cell proteasome prevents ADAMTS13 secretion. Thrombosis Research, 2016, 147, 16-23.	1.7	5
482	Incidence of lowâ€titre factor VIII inhibitors in patients with haemophilia A: metaâ€analysis of observational studies. Haemophilia, 2017, 23, e87-e92.	2.1	5
483	Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 407-428.	2.3	5
484	A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method. Haemophilia, 2018, 24, 156-161.	2.1	5
485	Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A. Haemophilia, 2019, 25, 521-526.	2.1	5
486	Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids. Journal of the American Medical Directors Association, 2019, 20, 1313-1317.e9.	2.5	5

#	Article	IF	Citations
487	Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study. Medical Principles and Practice, 2019, 28, 501-508.	2.4	5
488	Understanding the Impact of Aberrant Splicing in Coagulation Factor V Deficiency. International Journal of Molecular Sciences, 2019, 20, 910.	4.1	5
489	Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil. Blood Advances, 2019, 3, 3432-3435.	5.2	5
490	Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus. Haemophilia, 2019, 25, e30-e32.	2.1	5
491	Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients. Haematologica, 2019, 104, 1268-1276.	3.5	5
492	The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians. Journal of Clinical Medicine, 2020, 9, 3379.	2.4	5
493	Anti-TNF-Î± Treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, 1901-1908.	1.9	5
494	Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. Journal of Autoimmunity, 2021, 124, 102728.	6.5	5
495	Two novel heterozygote missense mutations of the ADAMTS13 gene in a child with recurrent thrombotic thrombocytopenic purpura. Blood Transfusion, 2013, 11, 241-4.	0.4	5
496	Factors Associated with Depressive Symptoms in Young Adults with Coronary Artery Disease: Tehran Heart Center's Premature Coronary Atherosclerosis Cohort (THC-PAC) Study. Iranian Journal of Psychiatry, 2016, 11, 214-223.	0.7	5
497	Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERSâ€IPS study. Journal of Thrombosis and Haemostasis, 2022, 20, 1106-1114.	3.8	5
498	Factor V (Arg 506-->Gln) mutation in young survivors of myocardial infarction. Thrombosis and Haemostasis, 1996, 75, 701-2.	3.4	5
499	Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII. Blood, 1999, 93, 1237-44.	1.4	5
500	Allele frequency of CYP2C9 gene polymorphisms in Iran. Thrombosis and Haemostasis, 2002, 88, 874-5.	3.4	5
501	Fibrinogen concentrates. Clinical Advances in Hematology and Oncology, 2009, 7, 788-90.	0.3	5
502	Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2. Blood Advances, 2022, 6, 4031-4040.	5.2	5
503	Two Naturally Occurring Mutations on FVII Gene (S363I-W364C) Altering Intrinsic Catalytic Activity. Thrombosis and Haemostasis, 2002, 88, 750-755.	3.4	4
504	The role of ADAMTS13 in the new pathogenesis of TTP. Hematology, 2005, 10, 47-48.	1.5	4

#	Article	IF	Citations
505	Changing epidemiology of the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran. Journal of Thrombosis and Haemostasis, 2006, 4, 701-702.	3.8	4
506	Functional characterization of a novel missense mutation identified in a Turkish patient affected by severe coagulation factor V deficiency. Haemophilia, 2012, 18, 205-210.	2.1	4
507	Drop of residual plasmatic activity of ADAMTS13 to undetectable levels during acute disease in a patient with adult-onset congenital thrombotic thrombocytopenic purpura. Blood Cells, Molecules, and Diseases, 2013, 50, 59-60.	1.4	4
508	A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity. Haematologica, 2015, 100, e87-e89.	3.5	4
509	Baseline factor <scp>VIII</scp> plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease. Haemophilia, 2016, 22, 564-569.	2.1	4
510	Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review. Haematologica, 2018, 103, e138-e140.	3.5	4
511	Polypharmacy in older adults with severe haemophilia. Haemophilia, 2018, 24, e1-e3.	2.1	4
512	Thromboelastometry. Reproducibility of duplicate measurement performed by the RoTemÂ® device. Thrombosis Research, 2018, 172, 139-141.	1.7	4
513	Next-generation DNA sequencing to identify novel genetic risk factors for cerebral vein thrombosis. Thrombosis Research, 2018, 169, 76-81.	1.7	4
514	Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects. TH Open, 2019, 03, e123-e131.	1.4	4
515	Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2019, 17, 666-669.	3.8	4
516	Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study. Thrombosis Research, 2019, 174, 84-87.	1.7	4
517	Thrombin Generation in Preterm Newborns With Intestinal Failure-Associated Liver Disease. Frontiers in Pediatrics, 2020, 8, 510.	1.9	4
518	Effect of different methods for outlier detection and rejection when calculating cut off values for diagnosis of lupus anticoagulants. Thrombosis Research, 2020, 190, 20-25.	1.7	4
519	Frequency of Factor V Arg506 Gin in Italians. Thrombosis and Haemostasis, 1996, 75, 694-694.	3.4	4
520	A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2010, 116, 726-726.	1.4	4
521	Is Hemophilia B Less Severe Than Hemophilia A? Results Of Global Coagulation Assays. Blood, 2013, 122, 2352-2352.	1.4	4
522	Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A. Haematologica, 2019, 104, e369-e372.	3.5	4

#	Article	IF	Citations
523	Introducing the Tehran Heart Center's Premature Coronary Atherosclerosis Cohort: THC-PAC Study. The Journal of Tehran Heart Center, 2015, 10, 34-42.	0.3	4
524	Current and Emerging Approaches for Pain Management in Hemophilic Arthropathy. Pain and Therapy, 2022, 11, 1-15.	3.2	4
525	Molecular characterization of a factor VII deficient patient supports the importance of the second epidermal growth factor-like domain. Haematologica, 2004, 89, 979-84.	3.5	4
526	Genetic aspects and research development in haemostasis. Haemophilia, 2008, 14, 113-118.	2.1	3
527	Analysis of the structural effects of four novel and a previously known mutations causing factor XI deficiency. Thrombosis and Haemostasis, 2009, 102, 603-606.	3.4	3
528	Response: Further thoughts on the â€œphantomâ€•Î”6/7 FXI isoform. Blood, 2010, 116, 1186-1187.	1.4	3
529	Reply to: The importance and challenge of pediatric trials of hemophilia drugs. Nature Medicine, 2014, 20, 466-466.	30.7	3
530	Research in haemophilia B â€“ approaching the request for high evidence levels in a rare disease. Haemophilia, 2015, 21, 4-20.	2.1	3
531	Reply to the letter by Iorio. Haemophilia, 2017, 23, e248-e249.	2.1	3
532	Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2018, 183, 825-828.	2.5	3
533	Novel variant in HPS3 gene in a patient with Hermansky Pudlak syndrome (HPS) type 3. Platelets, 2020, 31, 960-963.	2.3	3
534	Relationship between thrombin generation parameters and prothrombin fragment 1Â+Â2 plasma levels. International Journal of Laboratory Hematology, 2021, 43, e248-e251.	1.3	3
535	Evaluation of procoagulant imbalance in Cushingâ€™s syndrome after short- and long-term remission of disease. Journal of Endocrinological Investigation, 2022, 45, 9-16.	3.3	3
536	A homozygous duplication of the <I>FGG</i> exon 8-intron 8 junction causes congenital afibrinogenemia. Lessons learned from the study of a large consanguineous Turkish family. Haematologica, 2022, 107, 1064-1071.	3.5	3
537	The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders. HemaSphere, 2021, 5, e643.	2.7	3
538	Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 3739-3739.	1.4	3
539	Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study. Blood, 2018, 132, 3744-3744.	1.4	3
540	Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study. Blood, 2018, 132, 1142-1142.	1.4	3

#	Article	IF	Citations
541	Prospective Data Collection on Patients with Fibrinogen and Factor XIII Deficiencies: Prelimary Results of the PRO-RBDD Project. Blood, 2014, 124, 2838-2838.	1.4	3
542	Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates in Patients with Congenital Fibrinogen Deficiency: Final Analysis. Blood, 2015, 126, 4680-4680.	1.4	3
543	Autoimmune protein S deficiency and deep vein thrombosis after chickenpox. Thrombosis and Haemostasis, 1996, 75, 212-3.	3.4	3
544	Homozygous 2bp deletion in the human factor VII gene: a non-lethal mutation that is associated with a complete absence of circulating factor VII. Thrombosis and Haemostasis, 2000, 84, 635-7.	3.4	3
545	Homozygosity for a Thr575Met missense mutation in the catalytic domain associated with factor XI deficiency. Haematologica, 2005, 90, 418-9.	3.5	3
546	External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019. European Journal of Internal Medicine, 2022, 102, 63-71.	2.2	3
547	Risk of Myocardial Infarction and Polymorphisms in Candidate Genes. New England Journal of Medicine, 2003, 348, 1176-1177.	27.0	2
548	Vagaries of genetic association studies in myocardial infarction. Blood, 2003, 102, 1558-1560.	1.4	2
549	The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran. Haemophilia, 2011, 17, 820-821.	2.1	2
550	Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura. Journal of Thrombosis and Thrombolysis, 2012, 34, 416-418.	2.1	2
551	Treatment of chronic hepatitis C with pegylated interferonâ€Î± inÂa patient with recurrent autoimmune thrombotic thrombocytopenic purpura. Transfusion Medicine, 2013, 23, 66-68.	1.1	2
552	Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding. Experimental Hematology and Oncology, 2014, 3, 15.	5.0	2
553	Pregnancy outcome after a first episode of cerebral vein thrombosis: reply. Journal of Thrombosis and Haemostasis, 2017, 15, 1526-1526.	3.8	2
554	Minimal factorÂXIII activity level to prevent major spontaneous bleeds: reply. Journal of Thrombosis and Haemostasis, 2017, 15, 2280-2282.	3.8	2
555	Recombinant factorÂXIII Aâ€subunit in a patient with factorÂXIII deficiency and recurrent pregnancy loss. Journal of Thrombosis and Haemostasis, 2018, 16, 1052-1054.	3.8	2
556	Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed de novo mutation. Haemophilia, 2018, 24, e263-e266.	2.1	2
557	Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. European Journal of Internal Medicine, 2019, 68, e7-e11.	2.2	2
558	Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery: Reply. Journal of Thrombosis and Haemostasis, 2019, 17, 1405-1406.	3.8	2

#	Article	IF	Citations
559	Hypercoagulability and the risk of recurrence in young women with myocardial infarction or ischaemic stroke: a cohort study. BMC Cardiovascular Disorders, 2019, 19, 55.	1.7	2
560	Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban. Journal of Thrombosis and Thrombolysis, 2020, 49, 413-419.	2.1	2
561	Comparison of von Willebrand factor plateletâ€binding activity assays: ELISA overreads type 2B with loss of HMW multimers. Journal of Thrombosis and Haemostasis, 2020, 18, 2513-2523.	3.8	2
562	Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem. Advances in Therapy, 2021, 38, 2709-2716.	2.9	2
563	DETERMINATION OF ANTI-ADAMTS13 AUTOANTIBODIES IN THROMBOTIC TROMBOCITOPENIC PURPURA (TTP) PATIENTS: COMPARISON OF TWO DIFFERENT METHODS. Journal of Thrombosis and Haemostasis, 2007, 5, P-T-303-P-T-303.	3.8	2
564	Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 373-373.	1.4	2
565	In Vitro Expression Studies of Two Mutations on the Metalloprotease and First Cub Domains of the ADAMTS-13 Gene Leading to Severe ADAMTS-13 Deficiency and Chronic Recurrent TTP.. Blood, 2004, 104, 514-514.	1.4	2
566	Elevated Hematocrit Concentration and the Risk of Mortality and Vascular Events in Patients Undergoing Major Surgery.. Blood, 2012, 120, 2088-2088.	1.4	2
567	Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project). Blood, 2018, 132, 2465-2465.	1.4	2
568	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen. Blood, 2019, 134, 2365-2365.	1.4	2
569	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity. Blood, 2019, 134, 2366-2366.	1.4	2
570	Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency. Clinical Pharmacokinetics, 2022, 61, 505-513.	3.5	2
571	Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial. Blood, 2021, 138, 3184-3184.	1.4	2
572	Factors Associated with Anxiety in Premature Coronary Artery Disease Patients: THC-PAC Study. Acta Medica Iranica, 2016, 54, 261-9.	0.8	2
573	Worldwide SARS-CoV-2 haplotype distribution in early pandemic. PLoS ONE, 2022, 17, e0263705.	2.5	2
574	Lombardy diagnostic and therapeutic network of thrombotic microangiopathy. Orphanet Journal of Rare Diseases, 2022, 17, .	2.7	2
575	Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura. Blood Advances, 2022, 6, 5463-5466.	5.2	2
576	Factor V and Combined Factor V and VIII Deficiencies. , 0, , 306-310.		1

#	Article	IF	Citations
577	Pediatric stroke and ADAMTS genes. Blood, 2012, 120, 5097-5098.	1.4	1
578	Does the orphan medicinal product regulation assist or hinder access to innovative haemophilia treatment in Europe ?. Haemophilia, 2014, 20, 455-458.	2.1	1
579	Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. European Journal of Internal Medicine, 2014, 25, 847-852.	2.2	1
580	Plasma factor XIII level variations during menstrual cycle. Blood Coagulation and Fibrinolysis, 2016, 27, 786-790.	1.0	1
581	Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register. Internal and Emergency Medicine, 2019, 14, 1347-1352.	2.0	1
582	Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series. Journal of Thrombosis and Haemostasis, 2019, 17, 492-498.	3.8	1
583	The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. Age and Ageing, 2021, 50, 498-504.	1.6	1
584	IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. British Journal of Haematology, 2021, 192, 621-625.	2.5	1
585	Acquired hemophilia A and delta storage pool deficiency in a patient with indolent non-Hodgkin lymphoma. Platelets, 2021, , 1-3.	2.3	1
586	Development of a Specific Monoclonal Antibody to Detect Male Cells Expressing the RPS4Y1 Protein. International Journal of Molecular Sciences, 2021, 22, 2001.	4.1	1
587	Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. Haemophilia, 2021, 27, e441-e449.	2.1	1
588	Pro-coagulant imbalance in patients with community acquired pneumonia assessed on admission and one month after hospital discharge. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1699-1708.	2.3	1
589	Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease: REPLY from original authors Biguzzi et al. Journal of Thrombosis and Haemostasis, 2021, 19, 310-310.	3.8	1
590	Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies. Blood, 2019, 134, 4908-4908.	1.4	1
591	Risk Factors for Recurrence of Thrombotic Thrombocytopenic Purpura.. Blood, 2006, 108, 1060-1060.	1.4	1
592	Patients with Mild Hemophilia a with Discrepant FVIII Assays: Thrombin Generation and Bleeding Phenotype. Blood, 2014, 124, 2844-2844.	1.4	1
593	Clots from FXI-Deficient Patients Display a Reduced Fibrinolytic Resistance. Blood, 2014, 124, 4219-4219.	1.4	1
594	ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates. Blood, 2012, 120, 3383-3383.	1.4	1

#	Article	IF	Citations
595	Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates for the Treatment of Congenital Fibrinogen Deficiency. Blood, 2014, 124, 2817-2817.	1.4	1
596	Natural History of Patients Affected with Thrombotic Thrombocytopenic Purpura: Milan TTP Registry. Blood, 2016, 128, 3731-3731.	1.4	1
597	Genetic Risk Stratification to Minimize Inhibitor Risk with the Use of Recombinant Factor VIII Concentrates: A Sippet Analysis. Blood, 2016, 128, 325-325.	1.4	1
598	Factor VIII inhibitor and source of replacement therapy. Blood Transfusion, 2012, 10, 112-3.	0.4	1
599	Genome-wide association studies in myocardial infarction and coronary artery disease. The Journal of Tehran Heart Center, 2010, 5, 116-21.	0.3	1
600	The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients. Haemophilia, 2022, , .	2.1	1
601	Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A. Haemophilia, 2022, 28, 270-277.	2.1	1
602	Rare Bleeding Disorders. , 0, , 54-64.		0
603	Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients. Journal of Thrombosis and Haemostasis, 2010, 8, 416-418.	3.8	0
604	Foreword. Haemophilia, 2012, 18, 1-1.	2.1	0
605	Introduction and overview. Blood Reviews, 2015, 29, S1-S3.	5.7	0
606	Inherited Bleeding Disorders in Pregnancy: Rare Coagulation Factor Defects. , 2015, , 209-221.		0
607	Increased plasma levels of Von Willebrand factor (VWF) and Factor VIII (FVIII) during acute bacterial infection drive a pro-hemostatic imbalance and herald severe outcome in cirrhosis. Digestive and Liver Disease, 2016, 48, e13.	0.9	0
608	Back pain: An old cause in a young adult. European Journal of Internal Medicine, 2016, 28, e1-e2.	2.2	0
609	An unusual diagnosis in a 31-year-old man with abdominal pain and hyponatremia. Internal and Emergency Medicine, 2018, 13, 1233-1238.	2.0	0
610	Choices of factor <scp>VIII</scp> products in previously untreated patients with haemophilia A: A global survey. Haemophilia, 2018, 24, e266-e268.	2.1	0
611	60. FOUR YEARS EXPERIENCE OF PREIMPLANTATION GENETIC TESTING OF FOUR MONOGENIC DISORDERS (CYSTIC FIBROSIS, BETA-THALASSAEMIA, HEMOPHILIA A AND B). Reproductive BioMedicine Online, 2019, 39, e63-e64.	2.4	0
612	FRI-256-Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage. Journal of Hepatology, 2019, 70, e507.	3.7	0

#	Article	IF	Citations
613	Romeo and Juliet: Revisited (at the time of COVID-19). European Journal of Internal Medicine, 2020, 81, 94.	2.2	0
614	Procoagulant imbalance in patients with non-cirrhotic Chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis. Digestive and Liver Disease, 2020, 52, e1-e2.	0.9	0
615	Factor VIII/Protein C and not ADAMTS13/VWF:Ag ratio is a prognostic risk factor for patients with cirrhosis and low MELD score. Digestive and Liver Disease, 2020, 52, e13-e14.	0.9	0
616	International Society on Thrombosis and Haemostasis: Present and future. Journal of Thrombosis and Haemostasis, 2021, 19, 1599-1601.	3.8	0
617	Localization and Function of Platelet ADAMTS-13.. Blood, 2005, 106, 3967-3967.	1.4	0
618	Molecular Mapping of the Chloride Binding Site in von Willebrand Factor (VWF): Energetics and Conformational Effects on the ADAMTS-13 Interaction with Wild Type and Type 2B R1306W VWF Forms.. Blood, 2006, 108, 333-333.	1.4	0
619	Non-Sense-Mediated mRNA Decay in ADAMTS13 Gene Caused by 29 Nucleotide Deletion.. Blood, 2006, 108, 1061-1061.	1.4	0
620	Thrombospondin-1 as a Modulator of ADAMTS13 Activity.. Blood, 2007, 110, 3711-3711.	1.4	0
621	Genotyp-Phenotype Correlation in Congenital ADAMTS13 Deficient Patients. Blood, 2008, 112, 273-273.	1.4	0
622	ADAMTS13 Activity and Autoantibodies Subclasses as Recurrency Risk Predictors In Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2010, 116, 2532-2532.	1.4	0
623	Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype. Blood, 2011, 118, 2219-2219.	1.4	0
624	Identification of DEEP Vein Thrombosis GENETIC RISK Variants by NEXT GENERATION Sequencing of Hemostatic Genes. Blood, 2011, 118, 710-710.	1.4	0
625	Inherited Bleeding Disorders in Pregnancy: Rare Coagulation Factor Defects. , 2012, , 131-141.		0
626	Complications of Pregnancy in Women with Thrombotic Thrombocytopenic Purpura. Blood, 2012, 120, 3322-3322.	1.4	0
627	Rare Coding Single Nucleotide Variants of ADAMTS13 Are Associated with Deep Vein Thrombosis in a Next-Generation Sequencing Association Study. Blood, 2012, 120, 107-107.	1.4	0
628	Diagnostic relevance of ADAMTS13 activity: Evaluation of 28 patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome clinical diagnosis. Srpski Arhiv Za Celokupno Lekarstvo, 2013, 141, 466-474.	0.2	0
629	Rare Genetic Variants Of The Protein-Coding Area Of The Genome and The Risk Of Inhibitor Development: An Exome-Sequencing Study Of 28 Patients With Severe Hemophilia A. Blood, 2013, 122, 571-571.	1.4	0
630	Plasma FXIII LEVEL Variations During Menstrual CYCLE. Blood, 2013, 122, 4777-4777.	1.4	0

#	Article	IF	Citations
631	Characterization of Two Naturally Occurring Mutations in the Second Epidermal Growth Factor-Like Domain of Factor VII. Blood, 1999, 93, 1237-1244.	1.4	0
632	The Role of ADAMTS13-Specific Circulating Immune Complexes in Prediction of Recurrence of Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2014, 124, 1467-1467.	1.4	0
633	International databases open the door to improved care for rare bleeding disorders. The Journal of Haemophilia Practice, 2015, 2, 11-12.	0.4	0
634	Efficacy of Human Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and to Prevent Bleeding during and after Surgery in Subjects with Congenital Fibrinogen Deficiency. Blood, 2016, 128, 1404-1404.	1.4	0
635	Risk Differential in Inhibitor Development in the First Days of Treatment By Product Class: A Sippet Analysis. Blood, 2016, 128, 330-330.	1.4	0
636	Idelalisib Rapidly Improves Platelets Function in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 5566-5566.	1.4	0
637	Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study). Blood, 2016, 128, 207-207.	1.4	0
638	Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia â€" A in the Sippet Cohort Study. Blood, 2018, 132, 384-384.	1.4	0
639	Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology. Blood, 2018, 132, 222-222.	1.4	0
640	Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.. Blood, 2018, 132, 1184-1184.	1.4	0
641	Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project. Blood, 2018, 132, 2464-2464.	1.4	0
642	Efficacy and Pharmacokinetics of a New Fibrinogen Concentrate in Treating Acute Bleeding in Adolescent Patients with Congenital Fibrinogen Deficiency. Blood, 2018, 132, 2501-2501.	1.4	0
643	Efficacy and Safety of Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and for Surgical Prophylaxis in Subjects with Congenital Fibrinogen Deficiency â€" a Phase 3 Study. Blood, 2018, 132, 2502-2502.	1.4	0
644	Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study. Blood, 2018, 132, 3781-3781.	1.4	0
645	Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study. Blood, 2019, 134, 1093-1093.	1.4	0
646	Rare coagulation disorders: an emerging issue. Blood Transfusion, 2007, 5, 185-6.	0.4	0
647	Diagnosis and management of patients with von Willebrand's disease in Italy: an Expert Meeting Report. Blood Transfusion, 2018, 16, 326-328.	0.4	0
648	Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis". Blood Transfusion, 2019, 17, 86.	0.4	0

#	Article	IF	Citations
649	Von Willebrand disease combined with coagulation defects in Iran. Blood Transfusion, 2021, 19, 428-434.	0.4	0
650	Which Level of Emicizumab Is Necessary for a Good Hemostasis?. Blood, 2021, 138, 4247-4247.	1.4	0
651	Real-World Experience with Emicizumab Prophylaxis in the Milan Cohort: A Single-Center Experience. Blood, 2021, 138, 1038-1038.	1.4	0
652	Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study. Blood, 2021, 138, 2080-2080.	1.4	0
653	Factor VIII Epitope Analysis Using a Random Peptide Phage-Display Library Approach in the Sippet Cohort. Blood, 2021, 138, 3176-3176.	1.4	0
654	Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a. Blood, 2021, 138, 3185-3185.	1.4	0
655	Anti-Emicizumab Antibodies Do Not Cross-React with Mim8 in Vitro. Blood, 2021, 138, 3193-3193.	1.4	0
656	Obituary for Stefano Duga (1967â€“2021): A life for science. Journal of Thrombosis and Haemostasis, 2022, , .	3.8	0
657	Two naturally occurring mutations on FVII gene (S363I-W364C) altering intrinsic catalytic activity. Thrombosis and Haemostasis, 2002, 88, 750-5.	3.4	0
658	Congenital Bleeding: Autosomal Recessive Disorders. , 0, , 842-858.		0
659	Thrombotic Thrombocytopenic Purpura and Haemolytic Uraemic Syndrome (Congenital and Acquired). , 0, , 876-884.		0
660	9 BIC International Conference: Rome (Italy), 15-17 September 2017. Blood Transfusion, 2017, 15, s475-s518.	0.4	0
661	Pulmonary tumour thrombotic microangiopathy in a young man: clinical and immunohistochemical characterisation of a rare complication of gastric signet-ring cell carcinoma. Blood Transfusion, 2021, 19, 506-509.	0.4	0
662	Impact of a commercially available <scp>DOAC</scp> absorbent on two integrated procedures for lupus anticoagulant detection in plasma containing argatroban. International Journal of Laboratory Hematology, 2022, 44, .	1.3	0
663	ISTH Biennial Impact Report: Looking back and looking forward. Journal of Thrombosis and Haemostasis, 2022, 20, 1515-1517.	3.8	0